ArticleFrontiers in psychiatry2025
Comparative analysis of Attention Deficit Hyperactivity Disorder in China and worldwide based on the Global Burden of Disease study.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- National and subnational burden of mental disorders in China, 1990-2023: a systematic analysis of the Global Burden of Disease Study 2023.The Lancet regional health. Western Pacific · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by difficulties in maintaining attention, excessive activity, impulsive behavior, and challenges in organizing and executing tasks. These symptoms can pose challenges in various settings, including home, school, and work, imposing a significant burden not only on affected individuals and their families but also on the global healthcare system. Method: This study utilized open data from the Global Burden of Disease database covering the years 1990-2021 to analyze the characteristics of the burden of ADHD in China and worldwide, including incidence, prevalence, and adjusted lifespan for disability (DALYs). The Average Annual Percent Change (AAPC) and the corresponding 95% Confidence Interval (95% CI) were calculated using Joinpoint to reflect the trends in ADHD burden. A comprehensive comparative analysis of the differences in the burden of ADHD between China and the world was conducted in multiple dimensions, such as age and gender, using the R software. Statistical significance was indicated by a two-sided P-value of less than 0.05. Result: From 1990 to 2021, the age-standardized incidence rate (ASIR) of ADHD in China increased from 103.58 per 100,000 to 126.23 per 100,000, while globally, the ASIR decreased from 61.67 per 100,000 to 58.67 per 100,000. The age-standardized prevalence rate (ASPR) in China increased from 1987.98 per 100,000 to 2183.99 per 100,000, contrasting with the global decline from 1228.35 per 100,000 to 1108.89 per 100,000. The age-standardized DALY rate (ASDR) in China also increased from 24.27 per 100,000 to 26.73 per 100,000, however, it decreased from 14.94 per 100,000 to 13.49 per 100,000 globally. The Average Annual Percent Change (AAPC) for ASIR, ASPR, and ASDR in China were 0.64%, 0.28%, and 0.29%, respectively, indicating an upward trend. In contrast, the global AAPC for the burden of ADHD showed a negative trend, with values of -0.16%, -0.34%, and -0.34% for ASIR, ASPR, and ASDR, respectively. The influence of age and gender on the burden of ADHD is distinct, with the highest incidence, prevalence, and DALYs typically observed during childhood. Furthermore, males consistently demonstrate higher rates across these metrics when compared to females. Conclusion: While there has been a positive development in reducing the burden of ADHD globally, China faces a significant challenge with increasing rates. The focus on childhood and gender differences is crucial for tailored interventions and policies to address ADHD effectively.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.